diroximel fumarate   Click here for help

GtoPdb Ligand ID: 10525

Synonyms: ALKS-8700 | ALKS8700 | BIIB098 | Vumerity®
Approved drug Immunopharmacology Ligand
diroximel fumarate is an approved drug (FDA (2019), EMA (2021))
Compound class: Synthetic organic
Comment: Diroximel fumarate is a novel oral fumarate prodrug. It is rapidly converted to monomethyl fumarate, which is the same active metabolite of dimethyl fumarate.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 0
Rotatable bonds 7
Topological polar surface area 89.98
Molecular weight 255.07
XLogP -0.81
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC(=O)C=CC(=O)OCCN1C(=O)CCC1=O
Isomeric SMILES COC(=O)/C=C/C(=O)OCCN1C(=O)CCC1=O
InChI InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+
InChI Key YIMYDTCOUQIDMT-SNAWJCMRSA-N
No information available.
Summary of Clinical Use Click here for help
FDA approval of diroximel fumarate (October 2019) allows it use as a treatment for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Phase 3 study results indicate that diroximel fumarate has improved patient-reported gastrointestinal tolerability compared to dimethyl fumarate (Tecfidera®) [1].